2-bromo-4,5-methylenedioxyamphetamine | 151920-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 2-bromo-4,5-methylenedioxyamphetamine
• 英文别名: 2-(6-bromo-benzo[1,3]dioxol-5-yl)-1-methyl-ethylamine；2-bromo-4,5-methylenedioxyphenylisopropylamine；1-(6-bromo-1,3-benzodioxol-5-yl)propan-2-amine
• CAS: 151920-03-5
• 化学式: C₁₀H₁₂BrNO₂
• 分子量: 258.115
• InChiKey: PHCFFGXVMHXBGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Halogen treatment of heart attack and ischemic injury
  申请人：Fred Hutchinson Cancer Research Center

  公开号：US10201570B2

  公开（公告）日：2019-02-12

  The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.

  本发明涉及卤素化合物（包括碘化物）和卤代化合物（包括碘化物、硫化物和硒）在治疗和预防疾病和伤害方面的用途。本发明进一步涉及包含卤素化合物和/或卤化金属化合物的组合物，包括药物组合物，以及制造此类化合物和向需要的受试者施用此类组合物的方法。
• HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY
  申请人：Fred Hutchinson Cancer Research Center

  公开号：EP3104939A1

  公开（公告）日：2016-12-21
• USE OF HALOGEN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF TISSUE INJURY AND POST-INTENSIVE CARE SYNDROME
  申请人：Faraday Pharmaceuticals, Inc.

  公开号：EP3801565A1

  公开（公告）日：2021-04-14
• Antiparkinsonian Action of Phenylisopropylamines
  申请人：Caron G. Marc

  公开号：US20070027208A1

  公开（公告）日：2007-02-01

  A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the method is used to treat at least a motor symptom of Parkinson's disease; in some embodiments the method is used to treat at least a non-motor symptom of Parkinson's disease.
• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.